Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by YARDUMIAN, D. A.
Right arrow Articles by MACHIN, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by YARDUMIAN, D. A.
Right arrow Articles by MACHIN, S. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1988 British Society for Rheumatology

research-article

SUCCESSFUL TREATMENT OF RAYNAUD'S SYNDROME WITH ILOPROST, A CHEMICALLY STABLE PROSTACYCLIN ANALOGUE

D. A. YARDUMIAN1, D. A. ISENBERG3, M. RUSTIN2, G. BELCHER4, M. L. SNAITH, P. M. DOWD2 and S. J. MACHIN1

1Departments of Haematology, University College and The Middlesex Hospital Medical School London
2Departments of Dermatology, University College and The Middlesex Hospital Medical School London
3The Bloomsbury Rheumatology Department, University College and The Middlesex Hospital Medical School London
4Scherine Health Care Limited Burgess Hill, West Sussex, UK

Correspondence to: Address correspondence to Dr. D. A. Yardumian, The Department of Haematology. The Middlesex Hospital, Mortimer Street. London WIN 8AA. UK.

Twelve female patients with severe secondary Raynaud's phenomenon were treated in a randomized order with both placebo and Iloprost infusions. Infusions were for 5 hours on 3 consecutive days and lloprost was administered at variable dosage from 1.0 to 3.0 ng/kg/min. A 6-week follow-up period was used between the two sets of infusions. A significant number of patients reported lloprost had improved Raynaud's symptomatology compared with placebo and this effect lasted for up to 6 weeks. The number of attacks of Raynaud's as recorded by patients in diary books was similarly reduced after lloprost. Digital and nail-bed blood flows measured by laser-Doppler methods were increased for up to 6 weeks after lloprost, but not after placebo infusions. lloprost may be a useful therapeutic agent in the treatment of severe secondary Raynaud's syndrome.

KEY WORDS: Scleroderma, Raynaud's phenomenon, Vasodilation


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Vasc MedHome page
E. R Mohler III, B. Klugherz, R. Goldman, S. E Kimmel, M. Wade, and C. M Sehgal
Trial of a novel prostacyclin analog, UT-15, in patients with severe intermittent claudication
Vascular Medicine, November 1, 2000; 5(4): 231 - 237.
[Abstract] [PDF]

Home page
 ANN INTERN MEDHome page
D. B. Badesch, V. F. Tapson, M. D. McGoon, B. H. Brundage, L. J. Rubin, F. M. Wigley, S. Rich, R. J. Barst, P. S. Barrett, K. M. Kral, et al.
Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease: A Randomized, Controlled Trial
Ann Intern Med, March 21, 2000; 132(6): 425 - 434.
[Abstract] [Full Text] [PDF]

Home page
 VASC ENDOVASCULAR SURGHome page
G. Arpaia, C. Cimminiello, M. Sardina, F. Rossi, M. Aloisio, S. B. Curri, and G. Bonfardeci
Microcirculatory Effects of Iloprost in Patients with Suspected Secondary Raynaud Phenomenon
Vascular and Endovascular Surgery, January 1, 1995; 29(1): 37 - 42.
[Abstract] [PDF]

Home page
 ANGIOLOGYHome page
M. Engelhart and J. R. Seibold
The Effect of Local Temperature Versus Sympathetic Tone on Digital Perfusion in Raynaud's Phenomenon
Angiology, September 1, 1990; 41(9): 715 - 723.
[Abstract] [PDF]

Home page
 ANGIOLOGYHome page
M. Engelhart and J. R. Seibold
Cyanosis and Raynaud's Phenomenon: The Relation to Underlying Disease and Venous Abnormalities
Angiology, June 1, 1990; 41(6): 432 - 438.
[Abstract] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.